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Abstract
In mouse models of influenza, T cells can confer broad protection against multiple viral subtypes when antibodies raised
against a single subtype fail to do so. However, the role of T cells in protecting humans against influenza remains unclear.
Here we employ a translational nonhuman primate model to show that cross-reactive T cell responses play an important
role in early clearance of infection with 2009 pandemic H1N1 influenza virus (H1N1pdm). To ‘‘prime’’ cellular immunity, we
first infected 5 rhesus macaques with a seasonal human H1N1 isolate. These animals made detectable cellular and antibody
responses against the seasonal H1N1 isolate but had no neutralizing antibodies against H1N1pdm. Four months later, we
challenged the 5 ‘‘primed’’ animals and 7 naive controls with H1N1pdm. In naive animals, CD8+ T cells with an activated
phenotype (Ki-67+ CD38+) appeared in blood and lung 5–7 days post inoculation (p.i.) with H1N1pdm and reached peak
magnitude 7–10 days p.i. In contrast, activated T cells were recruited to the lung as early as 2 days p.i. in ‘‘primed’’ animals,
and reached peak frequencies in blood and lung 4–7 days p.i. Interferon (IFN)-c Elispot and intracellular cytokine staining
assays showed that the virus-specific response peaked earlier and reached a higher magnitude in ‘‘primed’’ animals than in
naive animals. This response involved both CD4+ and CD8+ T cells. Strikingly, ‘‘primed’’ animals cleared H1N1pdm infection
significantly earlier from the upper and lower respiratory tract than the naive animals did, and before the appearance of
H1N1pdm-specific neutralizing antibodies. Together, our results suggest that cross-reactive T cell responses can mediate
early clearance of an antigenically novel influenza virus in primates. Vaccines capable of inducing such cross-reactive T cells
may help protect humans against severe disease caused by newly emerging pandemic influenza viruses.
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Introduction
The emergence and rapid spread of a novel triple reassortant
H1N1 influenza virus in April 2009 raised fears of a new and severe
pandemic. Early reports from Mexico suggested that the 2009 virus
might be more pathogenic than typical seasonal strains [1]. It was
quickly determined that the virus’s hemagglutinin (HA) envelope
protein was derived from the ‘‘classical swine’’ lineage, and
therefore descended from the H1N1 virus that emerged in 1918
[2]. More troublingly, few individuals under age 65 appeared to
have antibodies capable of recognizing the emerging virus [3–5]. By
June 2009 the World Health Organization had declared the first
influenza pandemic of the 21st Century. At the same time,
manufacturers and health ministries raced to produce, approve
and deploy vaccines that could protect against the 2009 H1N1
pandemic virus (H1N1pdm) [6].
When pre-existing antibody responses are insufficient for
protection, T cell responses that recognize relatively well-
conserved peptide epitopes may play an important role in
promoting viral clearance and reducing influenza disease severity.
In mice CD8+ T cells primed by influenza viruses of one subtype
can mediate ‘‘heterosubtypic immunity’’ against challenge with
serologically distinct viruses in the absence of cross-reactive
antibody [7–11]. Accordingly, a recent study in ferrets suggested
that previous infection with seasonal influenza viruses reduced
shedding of H1N1pdm [12]. Similar serial infection studies in
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seasonal influenza strains can protect against lethal challenge with
H1N1pdm, while antibodies cannot [13]. But the role of T cells in
human immunity to influenza remains unclear. A retrospective
epidemiological study suggested that cellular immune responses
induced by recent infection might have protected individuals from
severe disease in the 1957 pandemic [14]. Similarly, cytotoxic T
lymphocyte activity was associated with reduced virus shedding in
a cohort of experimentally infected volunteers who had no
detectable antibody responses against the experimental strain [15].
More recently, in-vitro studies have shown that T cells from
human volunteers cross-react with peptide epitopes that are
conserved among distinct viral subtypes [16–19]. Furthermore, in
a prospective study of influenza vaccine effectiveness, the presence
of virus-specific T cell responses reduced elderly subjects’ risk of
developing clinically apparent influenza, while there was no
correlation between vaccine-induced antibody titers and influenza
risk [20]. Despite these findings, however, there is little direct
evidence from humans that T cells mediate protection from
influenza disease or enable rapid virus clearance.
We therefore developed a translational model of immunity to
influenza using rhesus macaques, which share a closer phyloge-
netic relationship with humans than mice or ferrets do. Macaques
have been used previously for influenza research, but T cell
responses have rarely been examined [21–29]. Interestingly,
however, one study of DNA-based vaccines in macaques suggested
that T cells alone might be capable of limiting replication of H5N1
viruses and protecting vaccinated animals against severe disease,
while vaccine strategies that induced both T cells and neutralizing
antibodies appeared to be even more effective [30]. In the present
study, we asked whether T cells ‘‘primed’’ by infection with a
seasonal human influenza virus would enable macaques to rapidly
clear subsequent challenge with H1N1pdm. We found evidence
that such cross-reactive T cell responses are indeed elicited by
infection with seasonal viruses in these animals and may serve to
limit virus replication after challenge with a heterologous 2009
pandemic isolate. Our results suggest that vaccines capable of
stimulating T cell responses could play an important role in
mitigating the severity of future influenza pandemics, when pre-
existing antibodies are not likely to be effective. The only currently
accepted correlate of vaccine-induced protection against influenza
is serum neutralizing antibody. We speculate that vaccine compo-
nents designed to induce strong cross-reactive T cell responses in
addition to antibodies may augment currently approved vaccine
modalities.
Results
A seasonal human influenza virus replicates in macaques
and induces detectable cellular immune responses
To model exposure of humans to seasonal influenza viruses
prior to the 2009 pandemic, we first inoculated 5 rhesus macaques
with a recent seasonal isolate, A/Kawasaki/173/2001 (K173,
H1N1). Hemagglutination-inhibition (HI) assays using serum from
these animals confirmed that they had no pre-existing neutralizing
antibody responses against K173 (Table 1). This isolate had
productively infected cynomolgus macaques in a previous study
[29]. Animals were inoculated with a total of 9 million pfu virus by
a combination of routes (nasal, ocular, tracheal), as described
previously [31]. After inoculation we detected infectious virus in
nasal secretions from 3 of the 5 animals (Fig. 1). Virus was also
isolated from tracheal secretions in a fourth animal, r02108 (data
not shown). Virus replication in nasal secretions peaked between 1
and 4 days after inoculation, reaching peak titers between 900 and
12,750 pfu/ml (Fig. 1), consistent with the kinetics and
magnitude of seasonal influenza virus replication in experimentally
inoculated humans [32]. We did not detect infectious K173 in
bronchoalveolar lavage (BAL) samples from any of the 5 animals
(data not shown), suggesting that this seasonal virus did not
replicate in the lower respiratory tract.
No influenza-derived CD8+ or CD4+ T cell epitopes have been
reported for infected macaques, so we could not use epitope-
specific reagents such as minimal optimal peptides or MHC
Author Summary
Antibodies against influenza target the highly mutable
proteins on the virus surface. Influenza pandemics are
caused by novel viruses whose surface proteins are so
different from previously circulating viruses as to be
unrecognizable by most individuals’ antibodies. We
hypothesized that T cells might be capable of reducing
the severity of infection with pandemic influenza viruses,
against which antibodies are ineffective. Experiments in
mice have supported this idea, but the ability of T cells to
protect humans against influenza has remained unclear.
We therefore tested our hypothesis in macaque monkeys,
whose physiology and immune systems closely resemble
those of humans. We used a seasonal virus to ‘‘prime’’
macaques to make immune responses against influenza
and found that these animals were able to control
infection with 2009 H1N1 pandemic influenza viruses
more effectively than animals that had not been ‘‘primed.’’
Protection was associated with T cell responses, but not
antibodies, that were quickly ‘‘recalled’’ after challenge
with the pandemic virus. Our results suggest that ‘‘cross-
reactive’’ T cells could play an important role in controlling
influenza in humans. Vaccines designed to induce strong T
cell responses in addition to antibodies could offer
enhanced protection against emerging influenza viruses.
Table 1. Serum antibody titers against seasonal virus K173.
K173-specific HI
a
animal
K173
prechallenge
day 28
post-
K173
H1N1pdm
prechallenge
day 21 post-
H1N1pdm
rh2306 ,10
b 320 128 320
r01072 ,10 64 64 320
r02027 ,10 64 64 80
r02108 ,10 40 64 160
r03079 ,10 64 64 40
r02002 na
c Na ,8 ,10
r03087 na Na ,8 ,10
r03089 na Na ,10 ,10
r03137 na Na ,10 ,10
r04052 na Na ,10 ,10
r04077 na Na ,10 ,10
r05092 na Na ,10 ,10
aserum HI titers against seasonal virus A/Kawasaki/173/2001
bHI assays
conducted using turkey red blood cells and animal serum with seasonal virus
K173. Detection limit 8 or 10, depending on lowest serum concentration
tested.
cna, not applicable: naive animals were not challenged with seasonal
virus K173.
doi:10.1371/journal.ppat.1002381.t001
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these animals. Therefore, to track induction of cellular immunity
against K173 we first measured activation of T cells in blood and
lung following virus inoculation. In acute viral infections,
‘‘activated’’ T cells express the proliferation marker Ki-67 and
high levels of the adhesion molecule CD38 [33]. HLA-DR was not
consistently upregulated on Ki-67+CD38+ T cells in our
experiments (Fig. S1). Expanding populations of CD8+ T cells
expressing this phenotype were detectable both in the periphery
(blood) and in the lung (BAL) within 7 days of inoculation in all 5
animals (Fig. 2). We did not directly assess the activation kinetics
of CD4+ T cells, but we can estimate the frequency of activated
CD4+ T cells using cells that express the T cell marker CD3, but
not CD8 (Fig. S2). Populations of activated CD3+CD8- T cells
also expanded in both compartments with similar kinetics, though
the frequency of activated CD8- T cells was much lower than that
of activated CD8+ T cells, particularly in the blood; the sole
exception to this trend was animal rh2306, in which 53.8% of
CD3+CD8- cells in BAL had an activated phenotype at day 7
(Fig. S3). Indeed, the highest levels of CD8+ T cell activation in
lung and blood were also observed in animal rh2306, the only
animal from which infectious K173 virus could not be isolated.
58.5% of this animal’s blood CD8+ T cells and 39.1% of its lung
CD8+ T cells were activated at the peak of its response in these
compartments, on days 7–10 post-infection.
To confirm that these expanding populations of activated T
cells represented an influenza virus-specific cellular immune
response, we performed interferon (IFN)-c Elispot assays using a
library of overlapping peptides representing the entire influenza
virus A (H1N1) proteome, with the exception of PB1F2. The
peptides in this library have between 99% and 100% amino acid
sequence identity with K173 proteins (See Table S1). The sum of
virus-specific T cell responses detected by Elispot at each
timepoint is shown in Fig. 3. Importantly, we detected no cells
secreting IFN-c in response to stimulation with influenza peptides
prior to infection in any animal. However, each animal made
detectable T cell responses against influenza peptides on at least
two timepoints after inoculation with K173. The total magnitude
of the virus-specific T cell response was greater than 1,000 spot-
forming cells (SFC) per million PBMC at one or more timepoints
in each animal, with peak magnitudes ranging from 1,495 to 3,745
SFC/million. Responses to a peptide pool representing the N-
terminal half of NP were immunodominant in all 5 animals (Fig.
S4). To determine the contribution of CD8+ T cells to the total
peptide-specific response, we repeated Elispot assays on cryopre-
served PBMC from day 7 post-infection using 2 peptide pools that
stimulated strong responses in each animal. In these assays we
determined the frequency of IFN-c-secreting cells in both whole
PBMC and in PBMC depleted of CD8+ cells. CD8+ cell depletion
Figure 2. Activated CD8+ T cells appear in blood and lung
within 7 days of inoculation with seasonal influenza virus
K173. We used a flow cytometric assay to enumerate CD8+ T cells with
an activated phenotype before and after K173 infection as described in
the text. Data plotted are the frequency of CD3
+ CD8
+ lymphocytes that
express both Ki-67 and CD38. Data are not available from animal r01072
at day 21 post-inoculation due to technical problems.
doi:10.1371/journal.ppat.1002381.g002
Figure 1. A seasonal human influenza virus replicates in rhesus
macaques. Five rhesus macaques were inoculated with 9 million
plaque-forming units (pfu) influenza virus A/Kawasaki/173/2001 (K173,
H1N1) by a combination of routes as described in the text. Animals had
no detectable antibodies against K173 at the time of inoculation. Virus
replication in nasal secretions was monitored using standard plaque
assays. Virus titer is expressed as pfu/ml nasal swab fluid.
doi:10.1371/journal.ppat.1002381.g001
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response to many pools, but for most animals at least one peptide
pool elicited IFN-c responses in both whole PBMC and the
depleted cell fraction (data not shown). Intracellular cytokine
staining (ICS) of peptide-stimulated PBMC allows the simulta-
neous and direct enumeration of peptide-specific CD4+ and
CD8+ T cells. ICS assays on cryopreserved PBMC using selected
peptide pools confirmed that, as a group, animals made both
CD4+ and CD8+ T cell responses against influenza virus antigens
(Table S2). Together, these data show that the seasonal human
influenza virus K173 can productively infect rhesus macaques and
that this infection induces detectable virus-specific cellular immune
responses that involve both CD4+ and CD8+ T cells, with
differential contributions of the CD4+ and CD8+ compartments
among animals.
Rapid recall and boosting of cellular immune responses
in ‘‘primed’’ animals upon challenge with H1N1pdm
By day 28 after infection all 5 animals made antibody responses
against the seasonal H1N1 virus K173, but they made no
detectable neutralizing antibodies against H1N1pdm (compare
Tables 1 and 2). We therefore next asked whether other immune
responses ‘‘primed’’ by K173 infection could affect the course of
infection with H1N1pdm. Four months after inoculating the first 5
animals with K173, we challenged them, along with 7 naive
control animals, with H1N1pdm isolate A/California/04/2009
(CA04).
We first assessed the kinetics of T cell activation in blood and
lung in both groups of animals. Activated CD8+ T cells were
detectable in blood as early as 2 days after inoculation with
H1N1pdm in ‘‘primed’’ animals and reached peak levels 5–7 days
after infection (Fig. 4a). In contrast, in naive animals expansion
of activated CD8+ T cells became detectable 4–7 days after
infection and reached peak levels 7–10 days after infection, similar
to our observations of CD8+ T cell activation following K173
infection in the ‘‘primed’’ animals (Fig. 4b, compare to Fig. 2).
Strikingly, activated CD8+ T cells appeared in the lungs of all 5
‘‘primed’’ animals within 4 days of H1N1pdm challenge. Indeed,
CD8+ T cell activation peaked on day 4 post-infection in 3 of the 5
‘‘primed’’ animals, and on day 7 post-infection for the remaining 2
(Fig. 4c). In contrast, the frequency of activated CD8+ T cells did
not increase above background levels until day 4 post-infection in
naive animals, and the peak of activation was not reached until
days 7–10 (Fig 4d). Despite this later initiation of cellular immune
responses, the frequency of activated CD8+ T cells in BAL
samples at the peak of the response was extremely high in 5 of the
7 naive animals (51.7%–72.1% of all CD8+ T cells) in comparison
to the frequencies observed in the other 2 naive animals or the 5
‘‘primed’’ animals (10.6%–28.1% of all CD8+ T cells). The timing
of peak CD8+ T cell activation in both blood and lung occurred
significantly earlier in ‘‘primed’’ than in naive animals (p=0.008
and 0.012, respectively; Fig. 4e), suggesting that memory CD8+ T
cell responses elicited by K173 were rapidly recalled upon
H1N1pdm challenge four months later. Similar to our observa-
tions after infection with the seasonal virus K173, the frequency of
activated CD3+CD8- cells remained low in the blood of both
naive and ‘‘primed’’ animals, rising above background levels only
in r01072 among the ‘‘primed’’ macaques and r02002 in the naive
group (Fig. S5). In contrast, there were modest increases in
activated CD3+CD8- cells in the BAL of ‘‘primed’’ animals on day
4 post-infection (peak frequency 5.2–13.8% of BAL CD3+CD8-
lymphocytes), but marked increases in the frequency of cells with
this phenotype between days 4 and 14 in naive animals (peak
frequency 7.0–63.9% of BAL CD3+CD8- lymphocytes), suggest-
ing that activated CD4+ T cells localized to the lung, but mostly
did not traffic through the blood, after H1N1pdm infection
(Fig. S5).
Next we determined whether ‘‘priming’’ of T cell responses by
K173 infection affected the magnitude of virus-specific responses
following H1N1pdm challenge. Since we were most interested in
potentially cross-reactive T cell responses ‘‘primed’’ by K173
Figure 3. Macaques mount virus-specific T cell responses after
K173 infection. We used an IFN-c Elispot assay to enumerate
influenza virus-specific T cells among the peripheral blood mononuclear
cells (PBMC) of infected macaques. PBMC were stimulated with 19 pools
of overlapping synthetic peptides that collectively represented the
influenza virus proteome, as described in the text. After subtracting
background signal from the results for each pool, the frequency of cells
responding to each pool were summed to give the total virus-specific
response magnitude. Results are expressed as the number of spot-
forming cells (SFC) per million PBMC. To be considered positive, the
frequency of peptide-specific SFC/million PBMC must be at least 3 times
larger than the background (no peptide) value. Asterisks indicate that
data are not available from animal r01072 from days 7 or 21 post-
inoculation due to technical problems.
doi:10.1371/journal.ppat.1002381.g003
Table 2. Serum antibody titers against pandemic virus CA04.
CA04-specific HI
a
animal
H1N1pdm
prechallenge
day 7 post-
H1N1pdm
day 21 post-
H1N1pdm
rh2306 ,8
b ,10 160
r01072 ,8 ,10 80
r02027 ,8 ,10 160
r02108 ,8 ,10 160
r03079 ,8 ,10 160
r02002 ,8 ,10 640
r03087 ,8 ,10 320
r03089 ,8 ,10 320
r03137 ,8 ,10 320
r04052 ,8 ,10 320
r04077 ,8 ,10 320
r05092 ,8 ,10 160
aserum HI titers against pandemic virus A/California/04/2009
bHI assays
conducted using turkey red blood cells and animal serum with pandemic virus
CA04. Detection limit 8 or 10, depending on lowest serum concentration
tested.
doi:10.1371/journal.ppat.1002381.t002
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these assays we used the same set of overlapping peptides
representing the entire influenza virus proteome as we did to
measure responses to the initial K173 infection in the ‘‘primed’’
animals, except these assays used peptides representing the CA04
(autologous) HA sequence in order to detect responses against the
divergent HA of the challenge virus. As shown in Fig. 5, ‘‘primed’’
animals swiftly mounted virus-specific T cell responses upon
challenge with H1N1pdm. These responses peaked on day 7 post-
infection in all 5 ‘‘primed’’ animals. The peak magnitude of the
Figure 4. Activated CD8+ T cell populations increase rapidly in the blood and lungs of ‘‘primed’’ animals after challenge with
H1N1pdm. Four months after infection with the K173 seasonal isolate, we challenged the 5 previously infected macaques (blue traces, solid
symbols) and 7 naive control animals (green traces, open symbols) with 9 million pfu of H1N1pdm isolate A/California/04/2009 (CA04) and monitored
the kinetics of CD8+ T cell activation. a and b, CD8+ T cell activation kinetics in blood. c and d, CD8+ T cell activation kinetics in lung, assessed using
cells recovered from bronchoalveolar lavage (BAL). e, Peak levels of activation are reached significantly earlier in both compartments in ‘‘primed’’
animals than in naive animals.
doi:10.1371/journal.ppat.1002381.g004
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PBMC in ‘‘primed’’ animals (range 1,770–14,545), an average
increase of 3.5-fold per animal (range 1.0–9.7-fold) upon infection
with H1N1pdm with respect to K173. In contrast, virus-specific T
cell responses peaked on or after day 10 post-infection in all 7
naive animals and reached an average peak magnitude of 2,244
SFC/million PBMC (range 620–3,930). The day on which the
peak T cell response occurred was significantly earlier in ‘‘primed’’
than naive animals (p=0.0035). Interestingly, however, virus-
specific T cell frequencies were markedly increased after
H1N1pdm infection in only 3 of 5 ‘‘primed’’ animals. Differences
in response magnitude were not significant at any point after
infection when comparing the ‘‘primed’’ and naive groups as a
whole, though they approached significance on day 7 (data not
shown). As for K173 infection, assays using CD8+ cell-depleted
PBMC showed that peptide-specific responses involved both
CD4+ and CD8+ T cells in ‘‘primed’’ and naive animals (data
not shown). ICS assays using selected peptide pools suggested that
the strongest recall responses in ‘‘primed’’ animals at 7–10 days
post-challenge were mediated by CD8+ T cells that secreted IFN-
c but not IL-2 (Table S3). This analysis showed a similar pattern
of cellular immune responses to H1N1pdm in naive animals at day
21 post-challenge (Table S3). T cells directed against the N-
terminal half of NP were immunodominant in all 5 ‘‘primed’’
animals, similar to our observations after infection with K173,
though these responses were co-dominant with populations
recognizing the C-terminal half of CA04 HA in r02027 and
r03079 (Fig. S6). Naive animals infected with CA04 tended to
have more broadly directed T cell responses. Populations
recognizing NP peptides were clearly immunodominant in 4 of
7 naive animals, while the other 3 animals’ responses were either
dominated by different specificities, or were more broadly
directed, lacking clearly immunodominant populations (Fig. S6).
Neutralizing antibody responses against H1N1pdm were not
detectable in either group of animals at day 7 after infection, when
both groups of animals appeared to clear infection, although
H1N1pdm-specific antibodies were detectable by day 21
(Table 2). To determine whether the animals made antibodies
capable of binding, but not neutralizing, H1N1pdm, we
performed enzyme-linked immunosorbent assays (ELISAs) using
purified HA proteins to capture serum antibodies. These assays
showed that at least some antibodies raised by K173 infection were
capable of binding a pandemic virus HA (Fig. 6). Furthermore,
H1N1pdm-HA-binding antibodies reached high titers within 7
days of infection in ‘‘primed’’ animals, while they were not
detectable until 21 days after infection in naive animals. Assays
using whole lysates of K173 or CA04 viruses gave similar results
(data not shown). Together, these data suggest that seasonal
influenza virus infection raised antibodies capable of binding, but
not neutralizing, H1N1pdm, though the level of these ‘‘cross-
binding’’ antibodies varied among ‘‘primed’’ animals.
Altogether, our results show that animals ‘‘primed’’ to make
influenza virus-specific T cell responses by infection with a
seasonal human influenza virus mount a stronger cellular immune
response upon H1N1pdm challenge, and initiate this response
more quickly, than naive animals do. Moreover, H1N1pdm-
specific neutralizing antibody responses develop later in infection
than T cell responses do in both ‘‘primed’’ and naive animals.
However, ‘‘primed’’ animals had varying levels of antibodies
capable of binding, but not neutralizing, H1N1pdm at the time of
pandemic virus challenge.
‘‘Primed’’ animals clear H1N1pdm more rapidly than
naive animals
Our measurements of cellular immune responses in ‘‘primed’’
animals were consistent with what would be expected for an
Figure 5. ‘‘Primed’’ animals mount stronger virus-specific T cell responses than naive animals after H1N1pdm challenge. T cell
responses against the viral proteome were measured using IFN-c Elispot as described in Fig. 3. Blue bars, ‘‘primed’’ animals; Green bars, naive animals.
doi:10.1371/journal.ppat.1002381.g005
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whether ‘‘primed’’ animals could clear infection earlier than naive
animals could. Indeed, although infectious H1N1pdm was
detected in nasal secretions from 6 of 7 naive animals, it was
detectable in only 3 of 5 ‘‘primed’’ animals (Fig 7a and b).
Moreover, virus titers in the nasal secretions of ‘‘primed’’ animals
were significantly lower than those in naive animals by day 5 post-
infection, showing that ‘‘primed’’ animals cleared H1N1pdm from
the upper respiratory tract earlier than naive animals did (Fig. 7c).
It is thought that robust replication in the lower respiratory tract
by avian influenza viruses contributes to their ability to cause
severe pneumonia [34,35]. Since virus replication in the lower
respiratory tract may increase the potential for severe disease, we
also evaluated H1N1pdm replication in this compartment in both
groups of animals. Infectious H1N1pdm was isolated from the
lung (BAL fluid) of all 7 naive animals, but from only 3 of 5
‘‘primed’’ animals (Fig. 7d and e). H1N1pdm titers reached
levels above 100,000 pfu/ml BAL fluid by day 2 post-infection in
3 of 7 naive animals, and were 3,000 pfu/ml or greater in 6 of 7
animals on day 4 post-infection. By contrast, H1N1pdm titers
never exceeded 100,000 pfu/ml in the lungs of ‘‘primed’’ animals,
and infectious virus was detected in only 2 animals (at titers of 650
and 50 pfu/ml) by day 4 post-infection. The difference in lung
virus load between ‘‘primed’’ and naive animals on day 4 was
significant (p,0.01; Fig. 7f). Importantly, H1N1pdm replication
was brought under control in the ‘‘primed’’ animals before
neutralizing antibodies specific for the challenge virus became
detectable, although ‘‘primed’’ animals had varying levels of
antibodies capable of binding, but not neutralizing, H1N1pdm at
the time of challenge, which reached high titers on day 7. Taken
together, our results indicate that previous infection with seasonal
influenza viruses can ‘‘prime’’ immunity that enables rapid
clearance of challenge with a newly emerging pandemic influenza
virus.
Discussion
It is widely accepted that neutralizing antibody responses are
major correlates of protection against influenza viruses; current
vaccine guidelines therefore stipulate that a serum antibody titer of
$1:40 in a hemagglutination inhibition assay will protect subjects
against antigenically matched strains [36]. However, neutralizing
antibodies fail to provide broad protection against multiple virus
subtypes. In mice T cell responses mediate such ‘‘heterosubtypic
immunity,’’ [37] with likely contributions from both CD4+ and
CD8+ subsets [38]. T cells could therefore play a particularly
important role in protection against newly emerging influenza
viruses against which few individuals have effective neutralizing
antibodies [39], but studies in inbred laboratory mice could
overestimate the capability of T cells to protect against infection.
The role of T cells in protecting humans against influenza
therefore remains unclear.
Here we used a macaque model to show that prior infection
with seasonal human influenza viruses induces strong T cell
responses that are rapidly recalled, and in some animals, boosted
in magnitude upon challenge with H1N1pdm. Animals ‘‘primed’’
by infection with the seasonal virus cleared H1N1pdm more
rapidly from the upper and lower respiratory tract than naive
animals, in the absence of pre-existing antibodies capable of
neutralizing H1N1pdm. Indeed, serum neutralizing antibodies
against H1N1pdm were undetectable in all ‘‘primed’’ and naive
animals prior to challenge with the pandemic virus. These
observations are consistent with the high degree of sequence
divergence between the seasonal H1N1 virus K173 and the
pandemic virus CA04 (HA amino acid identity 79.5%, Table S1),
and also with observations from ferrets and humans that infection
with recent seasonal influenza viruses does not appear to raise
neutralizing antibodies capable of recognizing 2009 pandemic
H1N1 strains [3–5,12]. T cell activation assays suggested that both
CD8+ and CD3+CD8- T cells responded to infection with
seasonal and pandemic influenza viruses in all ‘‘primed’’ animals.
Follow-up Elispot and ICS assays using selected peptide pools
agreed with these results.
Taken together, our results suggest that cross-reactive T cell
responses may play a key role in facilitating rapid clearance of
H1N1pdm in macaques. We speculate that cross-reactive CD8+ T
cells are most likely to be involved in killing infected cells, and
therefore may be the primary effector of early virus clearance in
‘‘primed’’ animals. However, cross-reactive CD4+ T cell responses
Figure 6. Infection with seasonal influenza viruses induces variable levels of antibody capable of binding H1N1pdm antigens. We
used purifiedhemagglutinin (HA) proteins to capture antibodies from macaqueserum.Antibodies were detected using ananti-IgG antibody coupled to
horseradish peroxidase, with enzymatic activity quantified using a colorimetric assay. Results are expressed in terms of sample absorbance at 450 nm.
Antigens used in each assay were as follows: a, Purified HA protein from A/New Caledonia/20/1999, a close antigenic match to K173. b, Purified HA from
A/California/06/2009, a close antigenic match to CA04. Assays using lysates of K173 or CA04 viruses gave similar results (data not shown).
doi:10.1371/journal.ppat.1002381.g006
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heterosubtypic immunity, by providing ‘‘help’’ to CD8+ T cells
and B cells, and perhaps most importantly by recruiting immune
cells to sites of virus replication [40].
There are important caveats to this interpretation of our results.
First, we detected antibodies capable of binding H1N1pdm HA
protein in ‘‘primed’’ animals at the time of CA04 challenge. The
role of such binding, but not neutralizing, antibodies in protection
against influenza remains unclear. A mouse study suggested that
antibody-mediated functions in addition to direct neutralization of
virions can contribute to virus clearance [41]. However, during the
2009 pandemic human subjects with high levels of pre-existing
antibodies capable of binding H1N1pdm, but low or undetectable
neutralizing antibody titers, were at high risk for severe influenza
complications, including lung damage associated with antibody-
mediated complement deposition in the respiratory tract [42]. In
human H1N1pdm infections, binding, non-neutralizing antibodies
therefore appear to be associated more with pathology than with
protection. Nonetheless, we cannot exclude the possibility that
such antibodies contributed to clearance of H1N1pdm in
‘‘primed’’ macaques.
Second, there was not a clear relationship between the
magnitude of T cell responses assessed by activation or Elispot
assays and levels of virus replication. Frequencies of activated T
Figure 7. ‘‘Primed’’ animals clear H1N1pdm infection more rapidly than naive animals. We used plaque assays to monitor replication of
H1N1pdm in the upper respiratory tract (nasal secretions) and lower respiratory tract (BAL) in ‘‘primed’’ (blue traces, solid symbols) and naive animals
(green traces, open symbols). a and b, kinetics of H1N1pdm replication in nasal secretions. c, By day 5 post-inoculation virus titers in nasal secretions
were significantly lower in ‘‘primed’’ than naive animals. d and e, H1N1pdm replication kinetics in the lung. f, By day 4 post-infection virus titers in
lung were significantly lower in ‘‘primed’’ than naive animals.
doi:10.1371/journal.ppat.1002381.g007
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‘‘primed’’ animals after infection with H1N1pdm, although the
frequencies of activated cells in blood were comparable in both
groups. T cell responses in blood detected by IFN-c Elispot were
also markedly higher in 3 ‘‘primed’’ animals (r01072, r02027 and
r02108) than in all other animals following H1N1pdm challenge.
These same 3 animals also had the highest peak levels of CD8+ T
cell activation in blood among the ‘‘primed’’ animals, and the
highest H1N1pdm virus titers in nasal secretions and/or BAL fluid
among the ‘‘primed’’ animals. On the other hand, there was no
direct relationship between the magnitude of T cell responses
detected by activation assays and Elispot in naive animals. These
observations could indicate that our peptide set is more likely to
detect cross-reactive recall responses ‘‘primed’’ by the epitope
sequences found in K173 than de novo responses to H1N1pdm-
derived epitopes. It is possible that sustained high virus titers in the
lungs of naive animals drove localized T cell proliferation [43,44],
resulting in strong responses in the lungs that were not yet
detectable in the periphery at our latest timepoint. Conversely,
early clearance of virus from the lungs of ‘‘primed’’ macaques
could have stunted this localized expansion of T cells. Accordingly,
the relatively high H1N1pdm titers in r01072, r02027 and r02108
could have driven greater expansion of virus-specific T cells in
these animals than in the other ‘‘primed’’ animals. Alternatively,
expanding populations of activated T cells in naive animals may
be functionally impaired and less able to secrete IFN-c in response
to peptide stimulation than T cells in ‘‘primed’’ animals who more
effectively control virus replication. Nonspecific ‘‘bystander’’
activation in the setting of high antigenic load may also contribute
to the differences in frequency between T cells with an activated
phenotype and cells that secrete cytokines in response to peptide
stimulation.
These caveats show that we have not yet fully elucidated the
mechanisms of cross-reactive immunity to influenza viruses in
macaques. Nonetheless our study establishes an important role for
T cells in limiting replication of H1N1pdm in these animals.
Future experiments in this system should take advantage of the
ability to specifically deplete immune cell subsets (CD4+ cells,
CD8+ cells, CD20+ cells, among others) to dissect the contribu-
tions of these various populations to immune protection conferred
by vaccination and prior infection.
Macaques are increasingly being used to model disease processes
caused by pathogenic influenza viruses [21,23,29,31,45], and to
evaluate new vaccine modalities [22,24,30,46-57]. Many of these
vaccine candidates, for example recombinant virus vectors, are well
suited for the induction of CD4+ and CD8+ T cell responses, but so
far most studies have focused on developing vectors expressing HA
genes only [24,47,54]. Perhaps as a result, the majority of macaque
studies have examined humoral responses to infection and/or
vaccination.Various adjuvantedvaccine preparations [49,51–53], a
cold-adapted H5N1 virus [22], and DNA vaccines [30,51,55] have
all been reported to induce cellular immunity to influenza antigens
in macaques, but the contribution of these responses to protection
from challenge has only rarely been directly evaluated.
Interestingly, one of these studies showed that vaccination with
plasmid DNA encoding only a consensus H5N1 nucleoprotein
sequence induced T cell responses capable of limiting replication
of a virulent H5N1 challenge, resulting in a 2-log reduction in
tracheal virus titers in comparison to naive animals by 6 days post-
infection [30]. Vaccines that included both NP and consensus
H5N1 HA sequences, and thus induced both T cells and
neutralizing antibody, were still more effective, reducing titers by
up to 5 logs by day 6. Here, we observed a significant 3–4-log
reduction in H1N1pdm titers in ‘‘primed’’ animals by day 4 or 5
post-infection in lower or upper respiratory tract respectively.
Laddy et al. did not measure T cell responses after H5N1 virus
challenge, so we cannot compare recall responses in their study to
those observed here, but the magnitude of T cell responses after
the K173 virus ‘‘prime’’ in our animals (average 2,202 SFC/
million PBMC; range 1,495–3,745) was similar to the magnitudes
they observed after DNA vaccination (1,000–2,000 SFC/million).
Differences in control of H5N1 and H1N1pdm challenge in these
two studies could therefore be due to multiple factors, including
immune response magnitude, relative contributions of T cells and
antibodies, virus tropism and route and/or dose of inoculation.
It has been difficult to define the role of T cells in human
immunity to influenza, since investigators must rely largely on
epidemiological data and a small number of in-vivo challenge
experiments. There is evidence that T cell responses may have
reduced susceptibility to clinically apparent influenza during the
1957 pandemic [14] and reduced disease severity in individuals
infected in 2009 [58]. Similarly, pre-existing T cell responses, but
not vaccine-induced antibody levels, correlated with reduced risk
for influenza disease in a prospective study of elderly subjects [20].
Virus shedding was also significantly reduced in a subset of
experimentally infected subjects who had virus-specific cytotoxic T
cell activity in the absence of detectable antibody [15]. Finally,
several recent studies have reported that human volunteers have T
cells capable of recognizing peptides derived from H5N1 avian
viruses and H1N1pdm, and/or peptide epitopes that are
conserved among these viruses and seasonal strains [16–19,59–
61]. Together, these studies show that humans are capable of
making cross-reactive T cell responses against influenza viruses,
though the role of these responses in protecting subjects from
infection or disease remains unclear.
Our results are congruent with these more circumstantial data
in humans, and consistent with the close phylogenetic relationship
between macaques and humans. Indeed, the magnitude and
kinetics of influenza virus replication in our animals closely
resembled those observed in experimentally inoculated humans
[32]. However one must remember that every animal model has
limitations, and even macaque experiments are not always
predictive of results in humans. For example, here we waited 4
months between the initial infection with seasonal viruses and
rechallenge with H1N1pdm. This is longer than the 4–8 weeks
that is typical for evaluations of heterosubtypic immunity in small
animals, but the interval between human influenza seasons (and
between pandemics) is of course longer still. In mice it appears that
the half-life of effector T cell responses, particularly in the
respiratory mucosa, is less than one year [62], suggesting that the
T cell responses observed in our study could wane below
protective levels in the interval between influenza seasons in
naturally infected or vaccinated humans. The rates at which
mucosal T cell responses decay in humans and primates are not
well understood, so this will be an important focus of future
studies. Furthermore, there may be important differences in T cell
immunobiology between macaques and humans that further limit
the translatability of our results.
Finally, our results shed new light on the potential goals of a
broadly reactive influenza vaccine. Recent studies have shown that
trivalent inactivated vaccines (TIVs) elicit T cell responses in a
minority of healthy adults [63], while live attenuated influenza
vaccines (LAIVs) can elicit higher-frequency T cells in more
subjects [64]. In contrast, a different group showed that LAIV
elicited CD8+ T cell responses in children, but neither TIVs nor
LAIVs stimulated cellular immunity in adults [65], while Co et al.
found that commercial vaccine formulations differ in their ability
to stimulate T cell responses in adult-derived cell lines [66]. Taken
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not consistently immunogenic for T cell responses in humans, and
are therefore unlikely to provide heterosubtypic protection against
emerging virus variants. In contrast, the rapid clearance of virus
observed in our ‘‘primed’’ animals may be sufficient to prevent
severe disease and death in the case of a rapidly spreading
pandemic caused by a serologically novel virus, which must be the
goal of any broadly protective vaccine.
We therefore propose that vaccines capable of consistently
inducing strong cross-reactive T cell responses (and/or of boosting
pre-existing ones) could provide an important measure of
protection against future influenza pandemics. The experiments
described here used a seasonal H1N1 virus to ‘‘prime’’ responses
for an H1N1pdm challenge, but in principle T cell responses could
cross-react with a broad range of isolates and subtypes, provided
that the specific epitopes they target are preserved among viruses.
In practice, sequences encoding T cell epitopes are likely to be
differentially conserved, suggesting that immunogens for future T-
cell-based vaccines will need to be chosen carefully [67]. Effective
induction of T cell responses would likely require vaccine
components that express viral antigens de novo in targeted cells,
such as plasmid DNA, live attenuated influenza viruses, or
recombinant vectors based on other viruses. Other than live
attenuated viruses, such modalities have not been widely tested as
influenza vaccines in humans or primates, but recent results
appear promising. For example, a replication-defective vaccinia
virus vector encoding influenza virus NP and matrix proteins was
shown to be safe and capable of inducing T cell responses in
humans; the efficacy of this vaccine candidate is currently being
evaluated [68]. Our results suggest that vaccine components
optimized to induce cross-reactive T cell responses could enhance
existing, antibody-based modalities by eliciting cross-reactive T
cell responses capable of blunting the replication of even divergent
influenza viruses.
Materials and Methods
Research animals and ethics statement
This study used rhesus macaques (Macaca mulatta) of Indian
descent. Animals were males and females (6 of each gender)
between the ages of 4 and 8 (average age 6.17 years). Experiments
were performed using the same stocks of seasonal and pandemic
viruses in 3 different waves in 2009 and 2010, with slightly
different sampling schedules. The study was conducted according
to the guidelines of the United States National Research Council
[69] and the Weatherall Report [70] under a protocol approved
by the University of Wisconsin Graduate School Animal Care and
Use Committee. All procedures (virus inoculations, blood draws,
bronchoalveolar lavages) were performed under ketamine or
ketamine/medetomidine anesthesia, and all efforts were made to
minimize suffering. Prior to inclusion in the study animals were
screened for the presence of common MHC class I alleles by PCR
using sequence-specific primers (PCR-SSP) as previously described
[71]. All animals chosen for this study expressed the high-
frequency allele Mamu-A*01.
Viruses and inoculations
A stock of the seasonal human influenza virus isolate A/
Kawasaki/173/2001 (H1N1) was produced on Madin-Darby
canine kidney (MDCK) cells using reverse genetics, as previously
described [72]. A/California/04/2009 (H1N1pdm) was isolated
on MDCK cells. Animals were inoculated with a total of 9 million
pfu virus via a combination of routes, as described previously [31].
In this method, virus is applied to the trachea (4 ml), tonsils
(0.5 ml) and conjunctivae (0.5 ml). Virus titer in nasal and tracheal
secretions as well as bronchoalveolar lavage (BAL) fluid was
determined using standard plaque assays performed in duplicate
on MDCK cells.
T cell activation assay
We measured activation of CD8+ T cells using an adaptation of
a previously described method [33]. Briefly, 100 ml whole blood
was stained with CD3 Pacific Blue clone SP34–2 (BD Biosciences,
San Jose, CA), CD38 FITC clone AT-1 (Stem Cell Technologies,
Vancouver, Canada), CD95 PE-Cy7 clone DX2 (eBioscience, San
Diego, CA), CD20 AF700 clone 2H7 (BioLegend, San Diego,
CA), and CD8 PerCP clone SK1 (BD Biosciences, San Jose, CA)
or CD8 APC-Cy7 clone RPA-T8 (BioLegend, San Diego, CA) for
30 minutes at room temperature in the dark. One ml FACSlyse
(BD Biosciences, San Jose, CA) was then added and incubated for
10 minutes at room temperature. The cells were then centrifuged
and washed twice with FACS buffer. After washes were complete,
100 ml FACS buffer containing 0.1% saponin was added to
permeabilize the cells, which were then stained intracellularly with
Ki-67 AF647 clone B56 (BD Biosciences, San Jose, CA), incubated
for 30 minutes at room temperature and washed twice with FACS
buffer. Alternately cells obtained from BAL fluid were treated in
the same fashion as whole blood but no FACSlyse was used;
instead cells were fixed in 1% paraformaldehyde for 15 minutes at
room temperature. Events were collected on a BD LSRII (BD
Biosciences, San Jose, CA) and analyzed using FlowJo software
(Tree Star Inc., Ashland, OR).
IFN-c Elispot assay
PBMC were separated from whole EDTA-treated blood by
Ficoll-Paque PLUS (GE Health Sciences) density centrifugation.
The PBMC were used directly in precoated ELISpot
PLUS kits
(MABTECH Inc., Mariemont, OH) for the detection of monkey
IFN-c according to the manufacturer’s protocols. Briefly, 1.0610
5
PBMC were used per well and incubated with pools of overlapping
17-mer peptides for approximately 18 hours at 37uCi n5 %C O 2.
19 peptide pools collectively represented the amino acid sequences
of all known influenza proteins except PB1F2. Peptides in pools
were diluted to a final concentration of 1 mM each. Each plate
contained a negative (no peptide) and positive (concanavalin A)
control. Results are expressed as the average number of spot-
forming cells (SFC) per million PBMC detected for each pool, with
the background (average number of SFC/million in negative
control wells) subtracted. Peptides representing HA sequences of
autologous H1N1pdm isolate CA04 were included in these
experiments after H1N1pdm infection. Experiments were con-
ducted in duplicate for each of 19 pools; the coefficient of variance
of results per pool ranged between 0 and 71%. Peptides were
obtained from BEI Resources (Manassas, VA). Results were
considered positive if wells contained an average of $5 spots and
the average SFC/million detected in peptide-containing wells was
at least threefold higher than the average number of spots in
negative control wells. The percent amino acid identity between
the peptide libraries used in Elispot assays and the challenge
viruses K173 and CA04 is shown in Table S1.
Intracellullar cytokine staining (ICS)
Previously isolated PBMC were thawed and placed in complete
RPMI-1640 containing 10% fetal calf serum (R10) and then
centrifuged to remove residual freezing media. PBMC were then
resuspended at 2x10
7 cells/ml and aliquoted into 1.2 ml cluster
tubes at 1 million PBMC per tube. The following was then added
to each tube: 1 ml anti-CD28 clone L293 (BD Biosciences, San
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CA), 2 mg brefeldin A (to halt protein transport) and 44 ml R10.
Next, peptide pools were added to each tube to a final
concentration of 1 mM per peptide. Phorbol 12-myristate 13-
acetate (PMA) at 100 ng/ml and ionomycin at 2 mg/ml was added
to one tube of PBMC from each animal as a positive control.
Tubes were then incubated at 37uCa t5 %C O 2 for six hours.
When incubation was complete, LIVE/DEAD violet viability stain
(Invitrogen, Carlsbad,CA) was added according to the manufac-
turer’s instructions and the following surface stain antibodies were
added: CD3 PerCP-Cy5.5 clone SP34–2 (BD Biosciences, San
Jose, CA), CD8 APC-Cy7 clone RPA-T8 (BioLegend, San Diego,
CA), and CD4 PE-Cy7 clone OKT4 (BioLegend, San Diego, CA).
Cells were then incubated for 30 minutes at room temperature in
the dark. Afterwards, cells were washed twice with FACS buffer
and fixed in 1% paraformaldehyde for 15 minutes. When fixation
was complete, cells were washed once in FACS buffer and left
overnight at 4uC. The following day cells were washed twice with
FACS buffer containing 0.1% saponin and then stained with the
intracellular antibodies IFN-c FITC clone 4S.B3 (BD Biosciences,
San Jose, CA) and IL-2 PE clone MQ1-17H12 (BD Biosciences,
San Jose, CA) for 50 minutes at room temperature in the dark.
After staining was complete cells were again washed twice with
FACS buffer containing 0.1% saponin and stored at 4uC. Events
were collected on a BD LSRII flow cytometer and analyzed using
FlowJo software.
Hemagglutination-inhibition (HI) assay
HI assays were performed using turkey red blood cells as
previously described [73]. Results are expressed as the reciprocal
serum titer at which inhibition of hemagglutination by the
indicated virus was no longer observed.
Antigen preparation
To prepare whole virus lysates for antibody-capture ELISAs,
supernatant containing virus grown on MDCK cells was overlaid
on a 25% sucrose cushion and spun at 75,000 x g for 2 hours at
4uC. When the spin was completed the supernatant was removed
and the virus pellet was resuspended overnight at 4uCi n5 0m M
Tris-HCl (pH 7.8) containing 0.5% Triton X-100. Purified HA
proteins expressed in 293 cells were purchased from Immune
Technology Corp. (New York, NY) for use in ELISAs.
Enzyme linked immunosorbent assay
We used antibody capture ELISA to detect antibodies in
macaque serum capable of binding influenza virus antigens,
regardless of their ability to neutralize viral infectivity. Briefly,
Immunlon 2HB plates (Thermo Fisher Scientific, Waltham, MA)
were coated with approximately 1 mg antigen (purified HA protein
or whole virus) in PBS at 4uC overnight. Antigen was removed and
plates were washed six times with PBS + 0.05% Tween-20. Plasma
was diluted 1:100 in PBS and 100 ml was added to each well.
Plates were incubated with diluted plasma at 37uC for 2 hours and
then washed six times with PBS + 0.05% Tween-20. To detect
bound macaque antibody, mouse anti-human IgG antibody clone
G18–145 conjugated to horseradish peroxidase (BD Biosciences,
San Jose, CA) was diluted 1:1000 in PBS and 100 ml were added to
each well and incubated at room temperature for one hour. The
plate was then washed six times with PBS + 0.05% Tween-20 and
SureBlue TMB Microwell Peroxidase substrate (KPL, Gaithers-
burg, MD) was added and incubated at room temperature. When
a blue color change was present in control wells 100 ml 1N HCl
was added to each well to stop the reaction. Absorbance at was
measured at 450 nm.
Statistical analysis
Analyses of the differences in timing of peak CD8+ T cell
activation, and in the magnitude of peptide-specific T cell
responses, virus titer and binding antibody responses in ‘‘primed’’
and naive animals were performed using the Welch-corrected two-
tailed t test in Prism software version 5.0c (GraphPad Software, La
Jolla, CA). Analyses of virus load were performed on log-
transformed data. Analysis of the differences in timing of peak T
cell response magnitude detected by Elispot were conducted using
the Wilcoxon rank sum test, since the peak occurred on the same
day for all ‘‘primed’’ animals.
Accession numbers for genes described in this study
The 2009 H1N1 pandemic influenza virus strain used to
challenge macaques was A/California/04/2009, whose genomic
RNAs have the following Genbank accession numbers: FJ969516
(PB2), GQ377049 (PB1), FJ969515 (PA), GQ117044 (HA),
FJ969512 (NP), FJ969517 (NA), FJ969513 (M), FJ969514 (NS).
The antibody ELISA assays used purified HA subtype 1 proteins
from the viruses A/New Caledonia/20/1999 (Genbank CY03
3622) and A/California/06/2009 (Genbank FJ966960). Sequenc-
es for virus A/Kawasaki/173/2001 are not currently available in
Genbank.
Supporting Information
Figure S1 HLA-DR is not consistently upregulated on
activated rhesus macaque T cells. In our initial experiments
we stained lymphocytes in fresh whole blood for a combination of
markers associated with activated, proliferating T cells, including
Ki-67, CD38, HLA-DR and Bcl-2. (The latter is thought to be
downregulated in activated T cells, while the rest are upregulated.)
However, we chose not to include HLA-DR staining in the
analyses presented in our manuscript, because we found that many
animals had relatively high levels of HLA-DRdim CD8+ T cells
prior to infection, making a clear definition of HLA-DR+ cells
difficult (data not shown). Furthermore, HLA-DR did not appear
to be consistently upregulated on CD8+ T cells that otherwise
showed the expected upregulation of markers associated with
activation. For example, at day 7 after infection, when activated
CD8+ T cell frequencies are typically high, animal r04052 shows
relatively dim staining with HLA-DR, but robust upregulation of
Ki-67 and CD38 (panel a). This is not due to a lack of HLA-DR-
specific antibody in the sample (far right). In contrast, HLA-DR
expression is clearly upregulated on activated CD8+ T cells in
animal r02108 at the same timepoint (panel b). Since HLA-DR is
known to be upregulated on activated human CD8+ T cells, we
are currently determining whether different HLA-DR-specific
antibody clones give clearer results in our assays. Unfortunately,
however, we will not be able to retrospectively analyze PBMC
from animals in these studies, since cryopreserved PBMC have
already been used for other assays.
(EPS)
Figure S2 CD3+CD8- cell frequencies approximate
those of CD3+CD4+ cells in T cell activation assay. Our
initial experiments used fresh PBMC and BAL cells and stained for
a combination of 8 markers that included CD3, CD8, CD38, Ki-
67 and HLA-DR, but did not include CD4. Unfortunately, due to
constraints in blood draw volume and cell yields, no BAL cells
remain; we were, however, able to cryopreserve PBMC from
some timepoints. To determine whether frequencies of activated
Cross-Reactive T Cells Against Influenza in NHP
PLoS Pathogens | www.plospathogens.org 11 November 2011 | Volume 7 | Issue 11 | e1002381(Ki-67+ CD38+)C D 3 +CD8-negative T cells measured in our
initial experiments accurately estimated frequencies of activated
CD4+ T cells, we thawed PBMC taken at day 10 post-infection
with the seasonal virus A/Kawasaki/173/2001 (K173; panels a-
d) or the pandemic virus A/California/04/2009 (H1N1pdm;
panels e-g) and stained them with antibodies specific for CD3,
CD4, CD8, CD38, Ki-67 and HLA-DR. a, initial results from
fresh PBMC without direct CD4 staining. b,W ec o m p a r e dt h e
frequency of activated CD4+ T cells measured in cryopreserved
day 10 samples with direct CD4 staining (blue squares) to
frequencies estimated by gating on CD3+CD8-negative events
in freshly stained samples (green circles). ca n dd ,A sac o n t r o l
for potential changes in lymphocyte quality after freezing and
thawing, we compared the frequency of activated CD8+ T cells
in fresh and frozen samples. Note that cryopreserved PBMC
were not available for animal r02108. We performed a similar
analysis of activated CD4+ Tc e l lf r e q u e n c ya f t e rH 1 N 1 p d m
infection in both previously infected (e) and naive animals (f). g,
comparison of the frequency of activated CD4+ T cells
measured in cryopreserved day 10 samples with direct CD4
staining (blue squares) to frequencies estimated by gating on
CD3+CD8-negative events in freshly stained samples (green
circles). Frequencies of activated CD4+ T cells measured
directly in cryopreserved samples generally agreed with
frequencies estimated by gating on CD3+CD8-negative popu-
lations in assays of lymphocytes in freshly obtained whole blood.
These results indicate that we are unlikely to have missed high-
frequency populations of activated CD4+ T cells using our
technique.
(EPS)
Figure S3 Activated CD8- T cells appear in blood and
lung within 7 days of inoculation with seasonal influenza
virus K173. We did not directly stain for CD4 in the T cell
activation experiments. However, since we did stain for both CD3
(a marker of all T cells) and CD8, we could use the same flow
cytometric assay described in Fig. 2 to enumerate CD8- T cells
with an activated phenotype, and thus estimate the frequency of
activated CD4+ T cells. Data plotted are the frequency of
CD3+CD8- lymphocytes that express both Ki-67 and CD38. Data
are not available from animal r01072 at day 21 post-inoculation
due to technical problems.
(EPS)
Figure S4 T cells recognizing NP antigens are immuno-
dominant in macaques infected with a seasonal H1N1
influenza virus. We assessed the ability of 19 different pools of
synthetic peptides representing influenza virus antigens to
stimulate secretion of IFN-c in PBMC from macaques infected
with the seasonal human virus K173. Peptides representing most
viral proteins were divided into 2 pools, with pool A containing
peptides from the N-terminal half and pool B containing peptides
from the C-terminal half. Responses directed against, e.g., NP-A
therefore recognize epitopes in the N-terminal half of the protein.
Colors indicate the proportion of the total virus-specific response
recognizing various peptide pools. The 4 peptide pools targeted by
the highest-frequency T cells in each animal are shown. Res-
ponses to all other pools are combined and shown in grey. Note
that the pools shown differ slightly among animals, as do vertical
scales.
(EPS)
Figure S5 Activated CD8- T cells reach lower peak
frequencies and peak earlier in ‘‘primed’’ than in naive
animals after challenge with H1N1pdm. We estimated the
frequency of activated CD4+ T cells in blood and lung of
‘‘primed’’ and naive animals after inoculation with H1N1pdm
isolate A/California/04/2009 as in Fig. S3. ‘‘Primed’’ animals are
shown using blue traces and solid symbols. Naive animals are
shown using green traces and open symbols. Data are not available
from animal r01072 at day 21 post-inoculation due to technical
problems. a and b, CD3+CD8- T cell activation kinetics in
blood. c and d, CD3+CD8- T cell activation kinetics in lung,
assessed using cells recovered from bronchoalveolar lavage
(BAL).
(EPS)
Figure S6 T cells recognizing NP antigens are immuno-
dominant in ‘‘primed’’ macaques after challenge with
H1N1pdm. We assessed the ability of 19 different pools of syn-
thetic peptides representing influenza virus antigens to stimulate
secretion of IFN-c in PBMC from macaques infected with the
pandemic human virus CA04. Peptide pools were constructed,
and data is displayed, as described for Fig. S2, with the addition of
pools specific for the HA of CA04. The 4–6 peptide pools targeted
by the highest-frequency T cells in each animal are shown.
Responses to all other pools are combined and shown in grey.
Note that the pools shown differ slightly among animals, as do
vertical scales.
(EPS)
Table S1 Amino acid identity between peptide library
viruses and challenge viruses used in this experiment.
This table depicts the % amino acid identity between challenge
viruses and synthetic peptide libraries used in this experiment.
Pairwise comparisons of challenge viruses to peptide libraries for
each viral protein are shown.
(PDF)
Table S2 Frequencies of influenza virus peptide-specif-
ic CD4+ and CD8+ T cells detected by intracellular
cytokine staining (ICS) after seasonal virus infection.
This table depicts the frequencies of CD4+ and CD8+ T cells
secreting cytokines in response to stimulation with selected
peptides. ICS assays were performed on cryopreserved peripheral
blood mononuclear cells (PBMC) sampled after infection with the
seasonal influenza virus A/Kawasaki/173/2001 (H1N1).
(PDF)
Table S3 Frequencies of influenza virus peptide-spe-
cific CD4+ and CD8+ T cells detected by intracellular
cytokine staining (ICS) after H1N1pdm challenge.
This table depicts the frequencies of CD4+ and CD8+ Tc e l l s
secreting cytokines in response to stimulation with selected
peptides. ICS assays were performed on cryopreserved periph-
eral blood mononuclear cells (PBMC) sampled after infection
with the pandemic influenza virus A/California/04/2009
(H1N1).
(PDF)
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